We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Cryosite is a diagnostics & research business based in Australia. Cryosite shares (CTE) are listed on the Australian Securities Exchange (ASX) and all prices are in Australian Dollars. Cryosite has a trailing 12-month revenue of around $10 million. If you're looking to buy shares, check out the steps below.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | $0.16 - $0.48 |
|---|---|
| 50-day moving average | $0.4051 |
| 200-day moving average | $0.3873 |
| Target price | N/A |
| PE ratio | 33.2308 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.013 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of A$0.432
| 1 week (2022-01-17) | -6.09% |
|---|---|
| 1 month (2021-12-24) | -2.92% |
| 3 months (2021-10-22) | 27.06% |
| 6 months (2021-07-23) | 2.86% |
| 1 year (2021-01-22) | 2.86% |
|---|---|
| 2 years (2020-01-24) | 715.09% |
Valuing Cryosite stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Cryosite 's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Cryosite 's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 33x. In other words, Cryosite shares trade at around 33x recent earnings.
That's comparable to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14).
Cryosite 's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.4 million (£734,697).
The EBITDA is a measure of a Cryosite 's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $10 million |
|---|---|
| Operating margin TTM | 10.6% |
| Gross profit TTM | $5.9 million |
| Return on assets TTM | 2.92% |
| Return on equity TTM | 14.38% |
| Profit margin | 6.51% |
| Book value | 0.008 |
| Market capitalisation | $21.1 million |
TTM: trailing 12 months
We're not expecting Cryosite to pay a dividend over the next 12 months.
Cryosite 's shares were split on 28 April 2004.
Over the last 12 months, Cryosite 's shares have ranged in value from as little as $0.16 up to $0.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Cryosite 's is 0.4927. This would suggest that Cryosite 's shares are less volatile than average (for this exchange).
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns management, comparator sourcing, import, export, validated transport solutions, and biological storage services to the clinical trial and research industry. The Cord Blood and Tissues Storage segment offers long term storage for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. Cryosite Limited was incorporated in 1999 and is based in South Granville, Australia.
With the total market cap of the crypto sector dropping by a whopping 10% within the last few hours, it seems as though the coming few days could be highly volatile for ETH.
What are the things to watch out for when buying your child's first laptop?
As Russia gets ready to outlaw its local crypto market, BTC could be faced with even greater volatility in the near future.
Heavyweight stars Fancis Ngannou and Cyril Gane headline UFC 270.
Shares in Rio Tinto have climbed more than 15% in the last month.
Here are the 10 biggest movers on the ASX for Friday 21 January 2022.
This leave-in conditioner transformed my unwashed mop into silky locks that would make Rapunzel envious.
Samsung's next flagship S22 phone will be, in its own less than subtle phrasing, "noteworthy".
A fun superhero series, an epic sci-fi and a dark teen drama are among our top picks this week.
